Prognostic significance of reverse transcriptase polymerase chain reaction for prostate-specific antigen in men with hormone-refractory prostate cancer

被引:46
|
作者
Kantoff, PW
Halabi, S
Farmer, DA
Hayes, DF
Vogelzang, NA
Small, EJ
机构
[1] Dana Farber Canc Inst, Dept Adult Oncol, Lank Ctr Genitourinary Oncol, Boston, MA 02115 USA
[2] Duke Univ, Med Ctr, Ctr Stat, Canc & Leukemia Grp B, Durham, NC USA
[3] Georgetown Univ, Med Ctr, Lombardi Canc Ctr, Washington, DC 20007 USA
[4] Univ Chicago, Med Ctr, Chicago, IL 60637 USA
[5] Univ Calif San Francisco, Ctr Comprehens Canc, San Francisco, CA 94143 USA
关键词
D O I
10.1200/JCO.2001.19.12.3025
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: To evaluate the prognostic significance of reverse transcriptase polymerase chain reaction (RT-PCR) detection of prostate-specific antigen (PSA) mRNA in the blood of men with hormone-refractory prostate cancer (HRPC). Patients and Methods: Peripheral blood was obtained from 193 men enrolled on Cancer and Leukemia Group B Study 9480, a prospective randomized comparison of three doses of suramin. RNA was isolated from the samples and assayed for the presence of PSA transcripts by RT-PCR. Results: RNA could be isolated in 156 (83%) of samples. PSA transcripts as measured by RT-PCR were detectable in 75 (48%) of the 156 patients. The median survival far those patients in whom no transcripts were detectable was 18 months (95% confidence interval [CI], 14 to 22 months) compared with 13 months (95% CI, 11 to 15 months) (P = .004) for those in whom transcripts were detectable. In a multivariate analysis in which other factors predictive of survival were used, RT-PCR for PSA provided independent prognostic information. Conclusion: RT-PCR for PSA predicts survival duration in a population of men with HRPC. J Clin Oncol 19:3025-3028. (C) 2001 by American Society of Clinical Oncology.
引用
收藏
页码:3025 / 3028
页数:4
相关论文
共 50 条
  • [1] Prognostic significance of baseline reverse transcriptase-PCR for prostate-specific antigen in men with hormone-refractory prostate cancer treated with chemotherapy
    Ross, RW
    Manola, J
    Hennessy, K
    Galsky, M
    Scher, H
    Small, E
    Kelly, WK
    Kantoff, PW
    [J]. CLINICAL CANCER RESEARCH, 2005, 11 (14) : 5195 - 5198
  • [2] Prognostic significance of reverse transcriptase polymerase chain reaction for prostate-specific antigen in metastatic prostate cancer: A nested study within CALGB 9583
    Halabi, S
    Small, EJ
    Hayes, DF
    Vogelzong, NJ
    Kantoff, PW
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (03) : 490 - 495
  • [3] Outcome of patients with hormone-refractory prostate cancer: Prognostic significance of prostate-specific antigen-doubling time and nadir prostate-specific antigen
    Tomioka, Susumu
    Shimbo, Masashi
    Amiya, Yoshiyasu
    Nakatsu, Hiroomi
    Murakami, Shino
    Shimazaki, Jun
    [J]. JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2008, 38 (01) : 36 - 42
  • [4] Reverse transcriptase-polymerase chain reaction for prostate-specific antigen may be a prognostic indicator in breast cancer
    Lehrer, S
    Terk, M
    Piccoli, SP
    Song, HK
    Lavagnini, P
    Luderer, AA
    [J]. BRITISH JOURNAL OF CANCER, 1996, 74 (06) : 871 - 873
  • [5] Quantitative reverse transcriptase polymerase chain reaction for prostate-specific antigen mRNA
    Galvan, B
    Christopoulos, TK
    [J]. CLINICAL BIOCHEMISTRY, 1997, 30 (05) : 391 - 397
  • [6] Reverse transcriptase polymerase chain reaction for prostate specific antigen in the management of prostate cancer
    Gomella, LG
    Raj, GV
    Moreno, JG
    [J]. JOURNAL OF UROLOGY, 1997, 158 (02): : 326 - 337
  • [7] Prostate-specific antigen doubling time is associated with survival in men with hormone-refractory prostate cancer
    Semeniuk, Ross C.
    Venner, Peter M.
    North, Scott
    [J]. UROLOGY, 2006, 68 (03) : 565 - 569
  • [8] Relationships between reverse transcriptase-polymerase chain reaction for prostate specific antigen, survival, and various prognostic laboratory factors in patients with hormone refractory prostate cancer
    Gandhok, NK
    Looney, S
    Koochekpour, S
    Sartor, O
    [J]. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2005, 23 (03) : 163 - 167
  • [9] Effect of prednisone on prostate-specific antigen in patients with hormone-refractory prostate cancer
    Sartor, O
    Weinberger, M
    Moore, A
    Li, AL
    Figg, WD
    [J]. UROLOGY, 1998, 52 (02) : 252 - 256
  • [10] Can prostate-specific antigen reverse transcriptase-polymerase chain reaction be used as a prospective test to diagnose prostate cancer?
    Goldman, HB
    Israeli, RS
    Lu, Y
    Lerner, JL
    Hollabaugh, RS
    Steiner, MS
    [J]. WORLD JOURNAL OF UROLOGY, 1997, 15 (04) : 257 - 261